Daniel Sims, DO
Hematology & Oncology · Provo, UTNPI 1669836532
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,060 of the $1,677 with a category attached, or 63.2%. It is spread thinly across 14 manufacturers, the largest accounting for just 23.7%. That places this record below the midpoint for hematology & oncology clinicians in UT, where the typical reported total is $2,350.
Across 39 payments — averaging $42.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$397
- Seagen Inc.$252
- Daiichi Sankyo Inc.$184
- Astellas Pharma US Inc$176
- Lilly USA, LLC$139
- Takeda Pharmaceuticals U.S.A., Inc.$129
- plus $401 from 8 others
What the payments were for
- Food & beverage$1,06063%
- Education$61737%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 6 | $397 |
| Seagen Inc. | 3 | $252 |
| Daiichi Sankyo Inc. | 4 | $184 |
| Astellas Pharma US Inc | 4 | $176 |
| Lilly USA, LLC | 3 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $129 |
| Novartis | 6 | $127 |
| Johnson & Johnson | 3 | $123 |
| Genentech USA, Inc. | 3 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Merck | 1 | $24 |
| Amgen | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,677 in reported general payments places this provider in the 45th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 13 | $170,474 |
| EliquisApixaban | 23 | $14,866 |
| Abiraterone Acetate | 53 | $7,851 |
| Anastrozole | 34 | $613 |
| Dexamethasone | 19 | $536 |
| Prednisone | 72 | $367 |
| Ondansetron OdtOndansetron | 18 | $256 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $240 |
| Prochlorperazine Maleate | 15 | $175 |
| Pregabalin | 11 | $154 |
| Gabapentin | 21 | $98 |
| Allopurinol | 11 | $34 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Provo
- Nathan RichProvo$14K
- Marc NuttallProvo$12K
- Steven WallentineProvo$7K
- Brandt EsplinProvo$4K
- Nathan PetersonProvo$3K
- David RirieProvo$1K
- Douglas SborovSalt Lake City$473K
- Belisario ArangoOgden$374K
- Mark LewisMurray$319K
- Daniel CourielSalt Lake City$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.